Tislelizumab Plus Chemotherapy Beneficial for Resectable NSCLC
Tislelizumab Plus Chemotherapy Beneficial for Resectable NSCLC
Tislelizumab Plus Chemotherapy Beneficial for Resectable NSCLC
Tecvayli (teclistamab-cqyv) Biweekly Dosing Approved by the U.S. FDA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Brain Cancer Risk Increased After Moderate/Severe, Penetrating TBI FRIDAY, Feb. 16. 2024 -- Moderate/severe and penetrating traumatic brain injury (TBI) are associated with an increased risk for subsequent development of brain cancer, according to a stud
FDA Approves Aurlumyn FDA Approves Aurlumyn (iloprost) as the First Medication to Treat Severe Frostbite February 14, 2024 -- The U.S. Food and Drug Administration approved Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce th
Ipsen’s Onivyde Regimen, a Potential New Standard-of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA PARIS, FRANCE, 13 February 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administ